Home › Breast Cancer › Texas
Breast Cancer clinical trials in Texas
176 studies for Breast Cancer are looking for participants at sites in Texas.
Cities in Texas
- Houston126 studies
- Dallas54 studies
- San Antonio45 studies
- Austin15 studies
- Fort Worth14 studies
- League City12 studies
- The Woodlands11 studies
- Sugar Land8 studies
- Irving8 studies
- El Paso7 studies
- Lewisville6 studies
- Lubbock6 studies
- Tyler5 studies
- McAllen4 studies
- Amarillo4 studies
- Killeen4 studies
- Baytown3 studies
- Abilene3 studies
- Denton3 studies
- Arlington3 studies
- Cypress3 studies
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- NEXT Houston, Galveston
- NEXT Oncology - PARENT, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07360314Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Baylor College of Medicine, Houston
- MD Anderson Cancer Center, Houston
- Harris Health System - Smith Clinic, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT05696626A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Renovatio Clinical - El Paso, El Paso
- JPS Health Network, Fort Worth
- Renovatio Clinical, The Woodlands
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT05894239A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- Oncology Consultants PA, Houston
RecruitingPhase 1
Ages 18 to 55 · Women · Updated Nov 12, 2026 · NCT07310420Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
- M D Anderson Cancer Center, Houston
Recruiting
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT05649072Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Texas Oncology - DFW ( Site 8000), Dallas
- Houston Methodist Hospital ( Site 0022), Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06797635Multi-center MRD Registry for Inflammatory Breast Cancer
- MD Anderson Cancer Center, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06966050An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- Next Oncology Austin, Austin
- The University of Texas Md Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07222267BostonGene and Exigent Genomic INsight Study
- Oncology Consultants, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06272864S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- UT Southwestern Clinical Center at Richardson/Plano, Richardson
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03418961Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
- UT MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Nov 12, 2026 · NCT05372640Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Research Facility, Dallas
- Research Facility, Houston
RecruitingPhase 1/2
All ages · All sexes · Updated Nov 12, 2026 · NCT06590857Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
- UT Southwestern, Dallas
Recruiting
Ages 18 to 80 · Women · Updated Nov 12, 2026 · NCT05245812A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Baylor Scott & White Research Institute -Texas Oncology, Dallas
- UT Southwestern Medical Center, Dallas
- South Texas Accelerated Research Therapeutics (START), LLC, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06827236Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- M D Anderson Cancer Center, Houston
Recruiting
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT03941756A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Texas Oncology - DFW ( Site 8009), Dallas
- UT Southwestern ( Site 0092), Dallas
- Texas Oncology - Northeast Texas ( Site 8002), Flower Mound
- and 6 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06966700Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT04557449ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- University of Texas Southwestern Medical Center, Dallas
- Houston Methodist Cancer Center, Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07007559Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
- UT Southwestern Medical Center, Dallas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT05693766Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
- MD Anderson Cancer Center, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT05964504A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07029399Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06324357A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center - Conroe, Conroe
- The University of Texas - M.D. Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
- and 3 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07318805Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Houston Methodist Hospital, Houston
- Oncology Consultants, Houston
Recruiting
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07214532Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Texas Oncology Central/South, Austin
- Texas Oncology DFW, Dallas
- University of Texas Southwestern Medical Center, Dallas
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06982521A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Hendrick Medical Center, Abilene
- World Research Link, Baytown
- Parkland Health and Hospital System, Dallas
- and 10 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07174336A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- JPS Health Network, Fort Worth
- Community Clinical Trials, Spring
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06790693E-Mindfulness Approaches for Living After Breast Cancer
- The Don and Sybil Harrington Cancer Center, Amarillo
RecruitingPhase 3
Ages 18 to 50 · All sexes · Updated Nov 4, 2026 · NCT06748222A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Texas MD Anderson Cancer Center, Houston
- Houston Methodist Hospital, Houston
- Oncology Consultants P.A., Houston
- and 1 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 4, 2026 · NCT07287098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Texas Oncology, Abilene
- Texas Oncology - Central / South Texas, Austin
- Mary Crowley Cancer Research, Dallas
- and 3 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The University of Texas - MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06400472A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07213791A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Texas Oncology - DFW (Sammons CC), Dallas
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07114601A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06760819Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- The Don and Sybil Harrington Cancer Center, Amarillo
- Houston Methodist San Jacinto Hospital, Baytown
- UT MD Anderson - The Woodlands, Conroe
- and 19 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Nov 4, 2026 · NCT05879926A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Texas Oncology - DFW, Dallas
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06695845A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Texas Oncology - DFW ( Site 8003), Dallas
- JPS Health Network ( Site 0067), Fort Worth
- Texas Oncology - Gulf Coast ( Site 8006), Houston
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07060807A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
- South Texas Accelerated Research Therapeutics, LLC (START), San Antonio
RecruitingPhase 1
Ages 18 and older · Women · Updated Nov 3, 2026 · NCT07524855A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- MD Anderson Cancer Center, Houston
- NEXT Dallas, Irving
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07578571From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.